Daily Medication Pearl: Maralixibat (Livmarli)

Maralixibat (Livmarli) is an ileal bile acid transporter inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.

Medication Pearl of the Day: Maralixibat (Livmarli)

Indication: Maralixibat (Livmarli) is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.

Insight:

  • Dosing:The recommended dosage is 380 mcg/kg once daily, taken 30 minutes before the first meal of the day.
  • Dosage forms: Oral solution 9.5 mg of maralixibat per mL.
  • Adverse events: Most common adverse reactions (≥5%) are diarrhea, abdominal pain, vomiting, fat-soluble vitamin deficiency, liver test abnormalities, gastrointestinal bleeding, and bone fractures.
  • Mechanism of action: Maralixibat is a reversible inhibitor of IBAT. It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum.
  • Manufacturer: Mirum Pharmaceuticals

Source

prescribinginformation.pdf (mirumpharma.com)